CHF Solutions Inc (NASDAQ:CHFS) hit a new 52-week low during trading on Thursday . The stock traded as low as $3.71 and last traded at $3.76, with a volume of 6984 shares. The stock had previously closed at $4.45.
Several equities research analysts recently commented on the company. ValuEngine raised CHF Solutions from a “hold” rating to a “buy” rating in a report on Saturday, March 9th. Zacks Investment Research raised CHF Solutions from a “hold” rating to a “buy” rating and set a $8.75 target price on the stock in a report on Wednesday, February 6th.
The firm has a market capitalization of $2.27 million, a P/E ratio of -0.08 and a beta of 2.78.
In related news, CEO John L. Erb purchased 9,523 shares of the company’s stock in a transaction on Tuesday, March 12th. The shares were bought at an average price of $5.25 per share, with a total value of $49,995.75. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. 7.30% of the stock is currently owned by corporate insiders.
An institutional investor recently bought a new position in CHF Solutions stock. Vanguard Group Inc bought a new stake in shares of CHF Solutions Inc (NASDAQ:CHFS) during the 3rd quarter, according to its most recent Form 13F filing with the SEC. The fund bought 33,048 shares of the company’s stock, valued at approximately $39,000. Vanguard Group Inc owned 0.46% of CHF Solutions as of its most recent SEC filing.
TRADEMARK VIOLATION NOTICE: This story was posted by Community Financial News and is the sole property of of Community Financial News. If you are accessing this story on another publication, it was copied illegally and republished in violation of U.S. & international trademark & copyright legislation. The legal version of this story can be accessed at https://www.com-unik.info/2019/03/14/chf-solutions-chfs-hits-new-1-year-low-at-3-71.html.
About CHF Solutions (NASDAQ:CHFS)
CHF Solutions, Inc, an early-stage medical device company, develops cardiac and coronary disease products primarily in the United States. The company focuses on commercializing the Aquadex FlexFlow system, which is indicated for temporary ultrafiltration treatment of patients with fluid overload who have failed diuretic therapy, and extended ultrafiltration treatment of patients with fluid overload who have failed diuretic therapy and require hospitalization.
Read More: What is a Derivative?
Receive News & Ratings for CHF Solutions Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CHF Solutions and related companies with MarketBeat.com's FREE daily email newsletter.